X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (67272) 67272
Book Review (10547) 10547
Newsletter (8109) 8109
Publication (4069) 4069
Newspaper Article (495) 495
Conference Proceeding (365) 365
Book Chapter (191) 191
Transcript (128) 128
Magazine Article (88) 88
Book / eBook (64) 64
Dissertation (60) 60
Web Resource (8) 8
Trade Publication Article (7) 7
Data Set (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Presentation (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55901) 55901
index medicus (55791) 55791
oncology (31023) 31023
female (28542) 28542
male (27885) 27885
middle aged (23508) 23508
cancer (23461) 23461
lung cancer, non-small cell (23090) 23090
lung neoplasms - drug therapy (22096) 22096
aged (22050) 22050
lung neoplasms - pathology (20291) 20291
carcinoma, non-small-cell lung - drug therapy (18186) 18186
lung cancer (16290) 16290
chemotherapy (15833) 15833
carcinoma, non-small-cell lung - pathology (15761) 15761
adult (14395) 14395
care and treatment (13593) 13593
research (12666) 12666
prognosis (10976) 10976
neoplasm staging (9883) 9883
antineoplastic combined chemotherapy protocols - therapeutic use (9196) 9196
cell line, tumor (9106) 9106
animals (9054) 9054
lung neoplasms - mortality (8947) 8947
non-small cell lung cancer (8889) 8889
treatment outcome (8536) 8536
aged, 80 and over (8464) 8464
lung neoplasms - genetics (8463) 8463
respiratory system (8178) 8178
tumors (7905) 7905
metastasis (7887) 7887
carcinoma, non-small-cell lung - genetics (7832) 7832
carcinoma (7443) 7443
carcinoma, non-small-cell lung - mortality (7249) 7249
survival (7218) 7218
apoptosis (7050) 7050
oncology, experimental (6982) 6982
analysis (6827) 6827
expression (6725) 6725
lung neoplasms - therapy (6586) 6586
antineoplastic agents - therapeutic use (6559) 6559
radiotherapy (6347) 6347
lung neoplasms - radiotherapy (6069) 6069
lung neoplasms - metabolism (5992) 5992
mice (5920) 5920
genetic aspects (5793) 5793
health aspects (5631) 5631
retrospective studies (5551) 5551
mutation (5508) 5508
surgery (5452) 5452
survival rate (5447) 5447
lung neoplasms - surgery (5248) 5248
carcinoma, non-small-cell lung - metabolism (4967) 4967
lung cancer, small cell (4940) 4940
combined modality therapy (4893) 4893
survival analysis (4855) 4855
therapy (4842) 4842
carcinoma, non-small-cell lung - radiotherapy (4817) 4817
cancer therapies (4780) 4780
carcinoma, non-small-cell lung - therapy (4734) 4734
gene expression (4681) 4681
carcinoma, non-small-cell lung - surgery (4608) 4608
cisplatin (4565) 4565
hematology, oncology and palliative medicine (4470) 4470
proteins (4468) 4468
abridged index medicus (4373) 4373
carcinoma, small cell - drug therapy (4319) 4319
development and progression (4005) 4005
cell biology (3965) 3965
gefitinib (3948) 3948
adenocarcinoma (3851) 3851
pharmacology & pharmacy (3809) 3809
patients (3789) 3789
cisplatin - administration & dosage (3752) 3752
nsclc (3732) 3732
antineoplastic agents - pharmacology (3676) 3676
medicine & public health (3654) 3654
immunohistochemistry (3520) 3520
disease-free survival (3462) 3462
follow-up studies (3405) 3405
cell lung-cancer (3344) 3344
antineoplastic agents (3312) 3312
kinases (3312) 3312
radiology, nuclear medicine & medical imaging (3282) 3282
gene expression regulation, neoplastic (3248) 3248
lung neoplasms - diagnosis (3245) 3245
medical prognosis (3223) 3223
medical research (3222) 3222
non-small cell lung carcinoma (3192) 3192
cell proliferation (3171) 3171
breast-cancer (3117) 3117
antimitotic agents (3113) 3113
medicine (3083) 3083
drug therapy (3061) 3061
biochemistry & molecular biology (3043) 3043
rna, small interfering - genetics (2991) 2991
non-small-cell lung cancer (2976) 2976
article (2958) 2958
diagnosis (2910) 2910
trial (2900) 2900
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (37) 37
Online Resources - Online (8) 8
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Robarts - May be requested in 6-10 wks (1) 1
Robarts - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (71546) 71546
Japanese (1169) 1169
French (1033) 1033
Chinese (896) 896
German (694) 694
Russian (173) 173
Polish (160) 160
Spanish (159) 159
Italian (126) 126
Korean (74) 74
Turkish (48) 48
Hungarian (45) 45
Dutch (42) 42
Czech (35) 35
Portuguese (32) 32
Danish (28) 28
Serbian (16) 16
Romanian (15) 15
Croatian (10) 10
Hebrew (10) 10
Swedish (10) 10
Finnish (9) 9
Norwegian (8) 8
Lithuanian (5) 5
Slovak (3) 3
Ukrainian (3) 3
Bulgarian (2) 2
Icelandic (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1116 - 1125
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2016, Volume 11, Issue 6, pp. 827 - 837
Journal Article
Nature Communications, ISSN 2041-1723, 2015, Volume 6, Issue 1, pp. 6377 - 6377
Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However,... 
GROWTH-FACTOR RECEPTOR | DRUG-SENSITIVITY | GEFITINIB | AMPLIFICATION | MODELS | GENE | MULTIDISCIPLINARY SCIENCES | MUTATION | ACQUIRED-RESISTANCE | KINASE INHIBITORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Recurrence | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Humans | Lung Neoplasms - metabolism | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | bcl-X Protein - genetics | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Adenocarcinoma - metabolism | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | Lung - metabolism | Gefitinib | ErbB Receptors - deficiency | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Aniline Compounds - pharmacology | ErbB Receptors - antagonists & inhibitors | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Retinoblastoma Protein - deficiency | Small Cell Lung Carcinoma - genetics | Sulfonamides - pharmacology | Adenocarcinoma - drug therapy | Disease Progression | Drug Resistance, Neoplasm - genetics | Small Cell Lung Carcinoma - pathology | Afatinib | Retinoblastoma Protein - genetics | Erlotinib Hydrochloride - pharmacology | Lung - drug effects | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - pharmacology | bcl-X Protein - metabolism | Proto-Oncogene Proteins c-bcl-2 - genetics | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2011, Volume 6, Issue 3, pp. 576 - 582
The aim of this prospective, observational, multicenter study was to examine the epidemiology and management costs of bone metastatic disease (BMD) in patients... 
Zoledronic acid | Costs | Bone metastases | Non-small cell lung cancer | Biphosphonates | SURVIVAL | SOLID TUMORS | PHASE-III | BREAST-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | PROSTATE-CANCER | DISEASE | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | COMPLICATIONS | Markov Chains | Prospective Studies | Bone Neoplasms - therapy | Follow-Up Studies | Humans | Middle Aged | Bone Neoplasms - secondary | Bone Neoplasms - epidemiology | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - secondary | Carcinoma, Large Cell - secondary | Carcinoma, Large Cell - epidemiology | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - economics | Aged, 80 and over | Diphosphonates - therapeutic use | Female | Retrospective Studies | Radiotherapy Dosage | France - epidemiology | Carcinoma, Squamous Cell - epidemiology | Carcinoma, Non-Small-Cell Lung - epidemiology | Carcinoma, Squamous Cell - therapy | Survival Rate | Treatment Outcome | Combined Modality Therapy | Lung Neoplasms - therapy | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - economics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - epidemiology | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Large Cell - economics | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Carcinoma, Squamous Cell - secondary | Aged | Bone Neoplasms - economics | Lung Neoplasms - economics | Small Cell Lung Carcinoma - therapy | Adenocarcinoma - economics | Adenocarcinoma - epidemiology | Neoplasm Staging | Small Cell Lung Carcinoma - epidemiology | Carcinoma, Large Cell - therapy | Small Cell Lung Carcinoma - economics | Index Medicus | Life Sciences | Santé publique et épidémiologie
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 187 - 199
Summary Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | COMPETING RISK | CLINICAL-TRIALS | THERAPY ONCOLOGY GROUP | CHEMORADIATION | INDUCTION | CARCINOMA | CHEMOTHERAPY | RADIATION-THERAPY | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Radiotherapy, Image-Guided | Chemoradiotherapy | Carcinoma, Large Cell - secondary | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Cetuximab | Paclitaxel - administration & dosage | Radiotherapy Dosage | Carboplatin - administration & dosage | Carcinoma, Squamous Cell - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiotherapy, Conformal | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Chemotherapy | Dosage and administration | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, pp. e0118195 - e0118195
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4106 - 4111
Purpose The American College of Chest Physicians (ACCP) produced an evidence-based guideline on treatment of patients with small-cell lung cancer (SCLC).... 
TRIAL | ETOPOSIDE | IRINOTECAN/CISPLATIN | ETOPOSIDE/CISPLATIN | CISPLATIN | ONCOLOGY | RANDOMIZED PHASE-III | DISEASE | Medical Oncology | Lung Neoplasms - therapy | Small Cell Lung Carcinoma - therapy | Prognosis | Humans | Practice Guidelines as Topic | Index Medicus
Journal Article